Fig 1: The marker protein elevation of ferroptosis can be reversed by NK-252. (a, b) The level of Nrf2 proteins was significantly increased by coculture with NK-252. (a, c, d) The expressions of 4-HNE and PTGS2 were significantly decreased in LTBP2-silenced gastric cancer cells after coculture with NK-252. Quantitative data are presented as mean s ± SD from three independent experiments. *P < 0.01 vs. the control.
Fig 2: LTBP2 mRNA expression in the CMS4 subtype of CRC. (a) In TCGA database, LTBP2 mRNA expression was obviously higher in the CMS4 subtype than in other CRC subtypes (P < 0.0001). (b) LTBP2 mRNA expression was significantly higher in SW620 and Caco2 (CMS4) than in other CRC cell lines (non-CMS4) and in a normal colorectal epithelial cell (NCM460).
Fig 3: LTBP2 siRNA transfection and validation in GC. (a) LTBP2 siRNA was transfected into AGS GC cells. (b) The silencing efficiency of the three sequences was assessed by the qRT-PCR. (c, d) The protein levels of LTBP2 were examined by Western blotting. (e–h) Gastric cancer cell lines AGS, BGC-823, MKN-28, and MGC-803 were transfected with LTBP2 siRNA and cell viabilities were assayed by the CCK-8 assay. Quantitative data are presented as means ± SD from three independent experiments. *P < 0.01 vs. the control.
Fig 4: Aberrant expression of LTBP2 in HCC patients. (A) The mRNA expression levels of LTBP2 determined by qRT-PCR in HCC tissues (n = 60) and adjacent nontumor tissues (n = 60); (B) Photographs of LTBP2 immunohistochemical staining in HCC tissues and adjacent non-tumor tissues; (C) The serum LTBP2 levels in patients with HCC and normal controls (n = 60) using ELISA; (D) Kaplan–Meier curves of survival rate differed between high and low LTBP2 expression in HCC patients. **P < .01 versus adjacent nontumor tissues; #P < .05 versus normal controls. ELISA = enzyme-linked immunosorbent assay, HCC = hepatocellular carcinoma, LTBP2 = latent TGF-ß binding protein 2, mRNA = messenger RNA, qRT-PCR = quantitative real time polymerase chain reaction.
Fig 5: Silencing LTBP2 decreases the proliferative ability of GC cells. The knockdown efficiency of LTBP2 in (A) SGC7901 and (B) BGC823 cells was investigated using western blotting and reverse transcription-quantitative chain reaction analyses. *P<0.05 and **P<0.01 vs. WT (C) Representative images of the colony-formation assay and quantification of the results indicating decreased colony-formation ability of GC cells with knockdown of LTBP2. *P<0.05 vs. Mock (D) CCK-8 assays indicating impaired proliferative ability of GC cells with knockdown of LTBP2. LTBP2, latent transforming growth factor-ß-binding protein 2; GC, gastric cancer; WT, wild-type; Mock, cells infected with mock lentivirus; OD, optical density; sh, short hairpin.
Supplier Page from Abcam for Anti-LTBP2 antibody